Amgen and AstraZeneca Report Two-Year NAVIGATOR Data for Tezspire in Severe Asthma

Amgen and AstraZeneca today presented two-year follow-up data from the Phase 3 NAVIGATOR trial evaluating Tezspire (tezepelumab) in patients with severe, uncontrolled asthma. The data showed that the reduction in annualized asthma exacerbation rates was maintained over two years of treatment, with Tezspire demonstrating a 70% reduction compared to placebo. Improvements in lung function and asthma control were also sustained.